MRNA · News · 20260810N

Licensing / Collaboration Deals

Moderna, Inc. · 2026-08-10 · Importance 34 · Surprise 42

Moderna provided Immunovant with a significant upfront payment tied to its IMVT-1402 drug program. The payment is cited as a catalyst alongside anticipated pivotal data readouts for IMVT-1402. The reporting indicates that the collaboration may support Immunovant’s longer-term financial profile despite the company’s current lack of revenue.

Key facts

• Contravisory Investment Management Inc. increased its stake in Moderna by 1,387.6% in Q2. source
• Contravisory acquired an additional 22,590 shares of Moderna, bringing its total to 24,218 shares valued at $1.696 million. source
• Institutional investors own 75.33% of Moderna's stock. source